Global Sildenafil Market Size study, by Product Type (Branded and Generics) by Application (Peripheral Vasodilator and Erectile Dysfunction) by End-User (Clinics, Hospitals, and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and Regional Forecasts 2022-2028Global Sildenafil Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Sildenafil is a type of phosphodiesterase which is used for the treatment of erectile dysfunction in men. It increases the blood flow to the penis to help men get an erection. The increase in prevalence of diabetes and obesity has led the adoption of Sildenafil across the forecast period. According to International Diabetes Federation, total adult population in Spain is 34,538,600 in year 2020 and around 10.5 % of this had diabetes that is 3,619,100 adults had diabetes. Furthermore, rising healthcare expenditure is also driving the growth for the sildenafil market for the forecasted period. Also, with the increasing research and development, the adoption & demand for Sildenafil is likely to increase the market growth during the forecast period. However, side effects caused by drugs impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Sildenafil market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the significant region across the world in terms of market share owing to the branded drugs and high acceptance of well-recognized drugs. Whereas, Europe is anticipated to exhibit highest growth rate over the forecast period 2022-2028. Factors such as established healthcare and research and development activities would create lucrative growth prospects for the Sildenafil market across Asia-Pacific region.

Major market player included in this report are:
Pfizer Inc.
Century Pharmaceuticals Ltd.
Polpharma
Deva Holdings
Actavis, Inc.
Accord-UK Ltd.
Mantra Pharma
ANGITA
Apotex Inc.
Bayer AG

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
Branded
Generics
By Application:
Peripheral Vasodilator
Erectile Dysfunction
By End-Users:
Clinics
Hospitals
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028

Target Audience of the Global Sildenafil Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Pfizer Inc.
Century Pharmaceuticals Ltd.
Polpharma
Deva Holdings
Actavis, Inc.
Accord-UK Ltd.
Mantra Pharma
ANGITA
Apotex Inc.
Bayer AG